www.fdanews.com/articles/150238-pharmacyclics-triggers-another-significant-milestone-payment-for-phase-iii-chronic-lymphocytic-leukemia-combination-trial

Pharmacyclics Triggers Another Significant Milestone Payment for Phase III Chronic Lymphocytic Leukemia Combination Trial

October 15, 2012

Pharmacyclics announced the international, randomized Phase III clinical trial of ibrutinib (PCI-32765) in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma has enrolled its fifth patient.
The Sacramento Bee